secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0000885725-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q4 rev $3.24B (+3.7% reported); adj. EPS $0.45 flat YoY; guides FY23 adj. EPS $1.86-$1.93
--------------------------------------------------------------------------------

- Q4 net sales $3.242B, up 3.7% reported, 7.1% organic; GAAP EPS $0.09 ($126M net income), adj. EPS $0.45.
- FY22 net sales $12.682B (+6.7% reported); GAAP EPS $0.45; adj. EPS $1.71 vs $1.63 prior year.
- FY23 guidance: reported sales growth 5-7%, organic 6-8%; adj. EPS $1.86-$1.93; Q1 adj. EPS $0.42-$0.44.
- Cardiovascular segment Q4 sales +6.4% reported; MedSurg +4.4% reported; US sales +10.5%.
- Agreed to acquire Apollo Endosurgery and majority stake in Acotec Scientific; AGENT DCB approved in Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000004/0000885725-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000004/bsx-20230201.htm
  HTML page:      https://secwatch.observer/filing/0000885725-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer